 | • レポートコード：MRC2-11QY01550 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は免疫性血小板減少性紫斑病治療薬のグローバル市場について調査・分析したレポートです。種類別（エルトロンボパグオラミン、フォスタマチニブ二ナトリウム、GL-2045、アバトロンボパグ、BI-655064、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別免疫性血小板減少性紫斑病治療薬の競争状況、市場シェア ・世界の免疫性血小板減少性紫斑病治療薬市場：種類別市場規模 2015年-2020年（エルトロンボパグオラミン、フォスタマチニブ二ナトリウム、GL-2045、アバトロンボパグ、BI-655064、その他） ・世界の免疫性血小板減少性紫斑病治療薬市場：種類別市場規模予測 2021年-2026年（エルトロンボパグオラミン、フォスタマチニブ二ナトリウム、GL-2045、アバトロンボパグ、BI-655064、その他） ・世界の免疫性血小板減少性紫斑病治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の免疫性血小板減少性紫斑病治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の免疫性血小板減少性紫斑病治療薬市場分析：米国、カナダ ・ヨーロッパの免疫性血小板減少性紫斑病治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの免疫性血小板減少性紫斑病治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の免疫性血小板減少性紫斑病治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの免疫性血小板減少性紫斑病治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Amgen Inc.、Baxalta Incorporated、Boehringer Ingelheim GmbH、Bristol-Myers Squibb Company、Eisai、Hansa Medical AB、Immunomedics, Inc.、Intas Pharmaceuticals Ltd.、Jiangsu Hengrui Medicine Co., Ltd.、Merck & Co., Inc.、Momenta Pharmaceuticals, Inc.、Novartis AG、Pfizer Inc. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Immune Thrombocytopenic Purpura Therapeutics Market
The global Immune Thrombocytopenic Purpura Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Immune Thrombocytopenic Purpura Therapeutics Scope and Market Size
Immune Thrombocytopenic Purpura Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Immune Thrombocytopenic Purpura Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Immune Thrombocytopenic Purpura Therapeutics market is segmented into
Eltrombopag Olamine
Fostamatinib Disodium
GL-2045
Avatrombopag
BI-655064
Others
Segment by Application, the Immune Thrombocytopenic Purpura Therapeutics market is segmented into
Hospital
Clinic
Others
Regional and Country-level Analysis
The Immune Thrombocytopenic Purpura Therapeutics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Immune Thrombocytopenic Purpura Therapeutics market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Immune Thrombocytopenic Purpura Therapeutics Market Share Analysis
Immune Thrombocytopenic Purpura Therapeutics market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Immune Thrombocytopenic Purpura Therapeutics business, the date to enter into the Immune Thrombocytopenic Purpura Therapeutics market, Immune Thrombocytopenic Purpura Therapeutics product introduction, recent developments, etc.
The major vendors covered:
Amgen Inc.
Baxalta Incorporated
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eisai
Hansa Medical AB
Immunomedics, Inc.
Intas Pharmaceuticals Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Merck & Co., Inc.
Momenta Pharmaceuticals, Inc.
Novartis AG
Pfizer Inc.
1 Study Coverage
1.1 Immune Thrombocytopenic Purpura Therapeutics Product Introduction
1.2 Market Segments
1.3 Key Immune Thrombocytopenic Purpura Therapeutics Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Type
1.4.2 Eltrombopag Olamine
1.4.3 Fostamatinib Disodium
1.4.4 GL-2045
1.4.5 Avatrombopag
1.4.6 BI-655064
1.4.7 Others
1.5 Market by Application
1.5.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Size, Estimates and Forecasts
2.1.1 Global Immune Thrombocytopenic Purpura Therapeutics Revenue 2015-2026
2.1.2 Global Immune Thrombocytopenic Purpura Therapeutics Sales 2015-2026
2.2 Global Immune Thrombocytopenic Purpura Therapeutics, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Immune Thrombocytopenic Purpura Therapeutics Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Immune Thrombocytopenic Purpura Therapeutics Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Immune Thrombocytopenic Purpura Therapeutics Competitor Landscape by Players
3.1 Immune Thrombocytopenic Purpura Therapeutics Sales by Manufacturers
3.1.1 Immune Thrombocytopenic Purpura Therapeutics Sales by Manufacturers (2015-2020)
3.1.2 Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Manufacturers (2015-2020)
3.2 Immune Thrombocytopenic Purpura Therapeutics Revenue by Manufacturers
3.2.1 Immune Thrombocytopenic Purpura Therapeutics Revenue by Manufacturers (2015-2020)
3.2.2 Immune Thrombocytopenic Purpura Therapeutics Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Immune Thrombocytopenic Purpura Therapeutics Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Immune Thrombocytopenic Purpura Therapeutics Revenue in 2019
3.2.5 Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Immune Thrombocytopenic Purpura Therapeutics Price by Manufacturers
3.4 Immune Thrombocytopenic Purpura Therapeutics Manufacturing Base Distribution, Product Types
3.4.1 Immune Thrombocytopenic Purpura Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Immune Thrombocytopenic Purpura Therapeutics Product Type
3.4.3 Date of International Manufacturers Enter into Immune Thrombocytopenic Purpura Therapeutics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2015-2020)
4.1.1 Global Immune Thrombocytopenic Purpura Therapeutics Sales by Type (2015-2020)
4.1.2 Global Immune Thrombocytopenic Purpura Therapeutics Revenue by Type (2015-2020)
4.1.3 Immune Thrombocytopenic Purpura Therapeutics Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Immune Thrombocytopenic Purpura Therapeutics Market Size Forecast by Type (2021-2026)
4.2.1 Global Immune Thrombocytopenic Purpura Therapeutics Sales Forecast by Type (2021-2026)
4.2.2 Global Immune Thrombocytopenic Purpura Therapeutics Revenue Forecast by Type (2021-2026)
4.2.3 Immune Thrombocytopenic Purpura Therapeutics Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2015-2020)
5.1.1 Global Immune Thrombocytopenic Purpura Therapeutics Sales by Application (2015-2020)
5.1.2 Global Immune Thrombocytopenic Purpura Therapeutics Revenue by Application (2015-2020)
5.1.3 Immune Thrombocytopenic Purpura Therapeutics Price by Application (2015-2020)
5.2 Immune Thrombocytopenic Purpura Therapeutics Market Size Forecast by Application (2021-2026)
5.2.1 Global Immune Thrombocytopenic Purpura Therapeutics Sales Forecast by Application (2021-2026)
5.2.2 Global Immune Thrombocytopenic Purpura Therapeutics Revenue Forecast by Application (2021-2026)
5.2.3 Global Immune Thrombocytopenic Purpura Therapeutics Price Forecast by Application (2021-2026)
6 North America
6.1 North America Immune Thrombocytopenic Purpura Therapeutics by Country
6.1.1 North America Immune Thrombocytopenic Purpura Therapeutics Sales by Country
6.1.2 North America Immune Thrombocytopenic Purpura Therapeutics Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Immune Thrombocytopenic Purpura Therapeutics Market Facts & Figures by Type
6.3 North America Immune Thrombocytopenic Purpura Therapeutics Market Facts & Figures by Application
7 Europe
7.1 Europe Immune Thrombocytopenic Purpura Therapeutics by Country
7.1.1 Europe Immune Thrombocytopenic Purpura Therapeutics Sales by Country
7.1.2 Europe Immune Thrombocytopenic Purpura Therapeutics Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Immune Thrombocytopenic Purpura Therapeutics Market Facts & Figures by Type
7.3 Europe Immune Thrombocytopenic Purpura Therapeutics Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Immune Thrombocytopenic Purpura Therapeutics by Region
8.1.1 Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Sales by Region
8.1.2 Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Market Facts & Figures by Type
8.3 Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Market Facts & Figures by Application
9 Latin America
9.1 Latin America Immune Thrombocytopenic Purpura Therapeutics by Country
9.1.1 Latin America Immune Thrombocytopenic Purpura Therapeutics Sales by Country
9.1.2 Latin America Immune Thrombocytopenic Purpura Therapeutics Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Immune Thrombocytopenic Purpura Therapeutics Market Facts & Figures by Type
9.3 Central & South America Immune Thrombocytopenic Purpura Therapeutics Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics by Country
10.1.1 Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Sales by Country
10.1.2 Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Market Facts & Figures by Type
10.3 Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Market Facts & Figures by Application
11 Company Profiles
11.1 Amgen Inc.
11.1.1 Amgen Inc. Corporation Information
11.1.2 Amgen Inc. Description and Business Overview
11.1.3 Amgen Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Products Offered
11.1.5 Amgen Inc. Related Developments
11.2 Baxalta Incorporated
11.2.1 Baxalta Incorporated Corporation Information
11.2.2 Baxalta Incorporated Description and Business Overview
11.2.3 Baxalta Incorporated Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Products Offered
11.2.5 Baxalta Incorporated Related Developments
11.3 Boehringer Ingelheim GmbH
11.3.1 Boehringer Ingelheim GmbH Corporation Information
11.3.2 Boehringer Ingelheim GmbH Description and Business Overview
11.3.3 Boehringer Ingelheim GmbH Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Products Offered
11.3.5 Boehringer Ingelheim GmbH Related Developments
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Corporation Information
11.4.2 Bristol-Myers Squibb Company Description and Business Overview
11.4.3 Bristol-Myers Squibb Company Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Products Offered
11.4.5 Bristol-Myers Squibb Company Related Developments
11.5 Eisai
11.5.1 Eisai Corporation Information
11.5.2 Eisai Description and Business Overview
11.5.3 Eisai Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Eisai Immune Thrombocytopenic Purpura Therapeutics Products Offered
11.5.5 Eisai Related Developments
11.6 Hansa Medical AB
11.6.1 Hansa Medical AB Corporation Information
11.6.2 Hansa Medical AB Description and Business Overview
11.6.3 Hansa Medical AB Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Products Offered
11.6.5 Hansa Medical AB Related Developments
11.7 Immunomedics, Inc.
11.7.1 Immunomedics, Inc. Corporation Information
11.7.2 Immunomedics, Inc. Description and Business Overview
11.7.3 Immunomedics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Products Offered
11.7.5 Immunomedics, Inc. Related Developments
11.8 Intas Pharmaceuticals Ltd.
11.8.1 Intas Pharmaceuticals Ltd. Corporation Information
11.8.2 Intas Pharmaceuticals Ltd. Description and Business Overview
11.8.3 Intas Pharmaceuticals Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Intas Pharmaceuticals Ltd. Immune Thrombocytopenic Purpura Therapeutics Products Offered
11.8.5 Intas Pharmaceuticals Ltd. Related Developments
11.9 Jiangsu Hengrui Medicine Co., Ltd.
11.9.1 Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
11.9.2 Jiangsu Hengrui Medicine Co., Ltd. Description and Business Overview
11.9.3 Jiangsu Hengrui Medicine Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Products Offered
11.9.5 Jiangsu Hengrui Medicine Co., Ltd. Related Developments
11.10 Merck & Co., Inc.
11.10.1 Merck & Co., Inc. Corporation Information
11.10.2 Merck & Co., Inc. Description and Business Overview
11.10.3 Merck & Co., Inc. Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Products Offered
11.10.5 Merck & Co., Inc. Related Developments
11.1 Amgen Inc.
11.1.1 Amgen Inc. Corporation Information
11.1.2 Amgen Inc. Description and Business Overview
11.1.3 Amgen Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Products Offered
11.1.5 Amgen Inc. Related Developments
11.12 Novartis AG
11.12.1 Novartis AG Corporation Information
11.12.2 Novartis AG Description and Business Overview
11.12.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Novartis AG Products Offered
11.12.5 Novartis AG Related Developments
11.13 Pfizer Inc.
11.13.1 Pfizer Inc. Corporation Information
11.13.2 Pfizer Inc. Description and Business Overview
11.13.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Pfizer Inc. Products Offered
11.13.5 Pfizer Inc. Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Immune Thrombocytopenic Purpura Therapeutics Market Estimates and Projections by Region
12.1.1 Global Immune Thrombocytopenic Purpura Therapeutics Sales Forecast by Regions 2021-2026
12.1.2 Global Immune Thrombocytopenic Purpura Therapeutics Revenue Forecast by Regions 2021-2026
12.2 North America Immune Thrombocytopenic Purpura Therapeutics Market Size Forecast (2021-2026)
12.2.1 North America: Immune Thrombocytopenic Purpura Therapeutics Sales Forecast (2021-2026)
12.2.2 North America: Immune Thrombocytopenic Purpura Therapeutics Revenue Forecast (2021-2026)
12.2.3 North America: Immune Thrombocytopenic Purpura Therapeutics Market Size Forecast by Country (2021-2026)
12.3 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size Forecast (2021-2026)
12.3.1 Europe: Immune Thrombocytopenic Purpura Therapeutics Sales Forecast (2021-2026)
12.3.2 Europe: Immune Thrombocytopenic Purpura Therapeutics Revenue Forecast (2021-2026)
12.3.3 Europe: Immune Thrombocytopenic Purpura Therapeutics Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Immune Thrombocytopenic Purpura Therapeutics Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Immune Thrombocytopenic Purpura Therapeutics Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Immune Thrombocytopenic Purpura Therapeutics Market Size Forecast by Region (2021-2026)
12.5 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size Forecast (2021-2026)
12.5.1 Latin America: Immune Thrombocytopenic Purpura Therapeutics Sales Forecast (2021-2026)
12.5.2 Latin America: Immune Thrombocytopenic Purpura Therapeutics Revenue Forecast (2021-2026)
12.5.3 Latin America: Immune Thrombocytopenic Purpura Therapeutics Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Immune Thrombocytopenic Purpura Therapeutics Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Immune Thrombocytopenic Purpura Therapeutics Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Immune Thrombocytopenic Purpura Therapeutics Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Immune Thrombocytopenic Purpura Therapeutics Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Immune Thrombocytopenic Purpura Therapeutics Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Immune Thrombocytopenic Purpura Therapeutics Market Segments
Table 2. Ranking of Global Top Immune Thrombocytopenic Purpura Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Eltrombopag Olamine
Table 5. Major Manufacturers of Fostamatinib Disodium
Table 6. Major Manufacturers of GL-2045
Table 7. Major Manufacturers of Avatrombopag
Table 8. Major Manufacturers of BI-655064
Table 9. Major Manufacturers of Others
Table 10. Global Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 11. Global Immune Thrombocytopenic Purpura Therapeutics Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 12. Global Immune Thrombocytopenic Purpura Therapeutics Sales by Regions 2015-2020 (K Pcs)
Table 13. Global Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Regions (2015-2020)
Table 14. Global Immune Thrombocytopenic Purpura Therapeutics Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global Immune Thrombocytopenic Purpura Therapeutics Sales by Manufacturers (2015-2020) (K Pcs)
Table 16. Global Immune Thrombocytopenic Purpura Therapeutics Sales Share by Manufacturers (2015-2020)
Table 17. Global Immune Thrombocytopenic Purpura Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global Immune Thrombocytopenic Purpura Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immune Thrombocytopenic Purpura Therapeutics as of 2019)
Table 19. Immune Thrombocytopenic Purpura Therapeutics Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. Immune Thrombocytopenic Purpura Therapeutics Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers Immune Thrombocytopenic Purpura Therapeutics Price (2015-2020) (USD/Pcs)
Table 22. Immune Thrombocytopenic Purpura Therapeutics Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Immune Thrombocytopenic Purpura Therapeutics Product Type
Table 24. Date of International Manufacturers Enter into Immune Thrombocytopenic Purpura Therapeutics Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Immune Thrombocytopenic Purpura Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 27. Global Immune Thrombocytopenic Purpura Therapeutics Sales Share by Type (2015-2020)
Table 28. Global Immune Thrombocytopenic Purpura Therapeutics Revenue by Type (2015-2020) (US$ Million)
Table 29. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Share by Type (2015-2020)
Table 30. Immune Thrombocytopenic Purpura Therapeutics Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 31. Global Immune Thrombocytopenic Purpura Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 32. Global Immune Thrombocytopenic Purpura Therapeutics Sales Share by Application (2015-2020)
Table 33. North America Immune Thrombocytopenic Purpura Therapeutics Sales by Country (2015-2020) (K Pcs)
Table 34. North America Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Country (2015-2020)
Table 35. North America Immune Thrombocytopenic Purpura Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 36. North America Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Country (2015-2020)
Table 37. North America Immune Thrombocytopenic Purpura Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 38. North America Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Type (2015-2020)
Table 39. North America Immune Thrombocytopenic Purpura Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 40. North America Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Application (2015-2020)
Table 41. Europe Immune Thrombocytopenic Purpura Therapeutics Sales by Country (2015-2020) (K Pcs)
Table 42. Europe Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Country (2015-2020)
Table 43. Europe Immune Thrombocytopenic Purpura Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 44. Europe Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Country (2015-2020)
Table 45. Europe Immune Thrombocytopenic Purpura Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 46. Europe Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Type (2015-2020)
Table 47. Europe Immune Thrombocytopenic Purpura Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 48. Europe Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Application (2015-2020)
Table 49. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Sales by Region (2015-2020) (K Pcs)
Table 50. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Region (2015-2020)
Table 51. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Revenue by Region (2015-2020) (US$ Million)
Table 52. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Region (2015-2020)
Table 53. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 54. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Type (2015-2020)
Table 55. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 56. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Application (2015-2020)
Table 57. Latin America Immune Thrombocytopenic Purpura Therapeutics Sales by Country (2015-2020) (K Pcs)
Table 58. Latin America Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Country (2015-2020)
Table 59. Latin Americaa Immune Thrombocytopenic Purpura Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 60. Latin America Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Country (2015-2020)
Table 61. Latin America Immune Thrombocytopenic Purpura Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 62. Latin America Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Type (2015-2020)
Table 63. Latin America Immune Thrombocytopenic Purpura Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 64. Latin America Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Application (2015-2020)
Table 65. Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Sales by Country (2015-2020) (K Pcs)
Table 66. Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Country (2015-2020)
Table 67. Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 68. Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Country (2015-2020)
Table 69. Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 70. Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Type (2015-2020)
Table 71. Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 72. Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Application (2015-2020)
Table 73. Amgen Inc. Corporation Information
Table 74. Amgen Inc. Description and Major Businesses
Table 75. Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 76. Amgen Inc. Product
Table 77. Amgen Inc. Recent Development
Table 78. Baxalta Incorporated Corporation Information
Table 79. Baxalta Incorporated Description and Major Businesses
Table 80. Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. Baxalta Incorporated Product
Table 82. Baxalta Incorporated Recent Development
Table 83. Boehringer Ingelheim GmbH Corporation Information
Table 84. Boehringer Ingelheim GmbH Description and Major Businesses
Table 85. Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. Boehringer Ingelheim GmbH Product
Table 87. Boehringer Ingelheim GmbH Recent Development
Table 88. Bristol-Myers Squibb Company Corporation Information
Table 89. Bristol-Myers Squibb Company Description and Major Businesses
Table 90. Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. Bristol-Myers Squibb Company Product
Table 92. Bristol-Myers Squibb Company Recent Development
Table 93. Eisai Corporation Information
Table 94. Eisai Description and Major Businesses
Table 95. Eisai Immune Thrombocytopenic Purpura Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. Eisai Product
Table 97. Eisai Recent Development
Table 98. Hansa Medical AB Corporation Information
Table 99. Hansa Medical AB Description and Major Businesses
Table 100. Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 101. Hansa Medical AB Product
Table 102. Hansa Medical AB Recent Development
Table 103. Immunomedics, Inc. Corporation Information
Table 104. Immunomedics, Inc. Description and Major Businesses
Table 105. Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 106. Immunomedics, Inc. Product
Table 107. Immunomedics, Inc. Recent Development
Table 108. Intas Pharmaceuticals Ltd. Corporation Information
Table 109. Intas Pharmaceuticals Ltd. Description and Major Businesses
Table 110. Intas Pharmaceuticals Ltd. Immune Thrombocytopenic Purpura Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 111. Intas Pharmaceuticals Ltd. Product
Table 112. Intas Pharmaceuticals Ltd. Recent Development
Table 113. Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
Table 114. Jiangsu Hengrui Medicine Co., Ltd. Description and Major Businesses
Table 115. Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 116. Jiangsu Hengrui Medicine Co., Ltd. Product
Table 117. Jiangsu Hengrui Medicine Co., Ltd. Recent Development
Table 118. Merck & Co., Inc. Corporation Information
Table 119. Merck & Co., Inc. Description and Major Businesses
Table 120. Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 121. Merck & Co., Inc. Product
Table 122. Merck & Co., Inc. Recent Development
Table 123. Momenta Pharmaceuticals, Inc. Corporation Information
Table 124. Momenta Pharmaceuticals, Inc. Description and Major Businesses
Table 125. Momenta Pharmaceuticals, Inc. Immune Thrombocytopenic Purpura Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 126. Momenta Pharmaceuticals, Inc. Product
Table 127. Momenta Pharmaceuticals, Inc. Recent Development
Table 128. Novartis AG Corporation Information
Table 129. Novartis AG Description and Major Businesses
Table 130. Novartis AG Immune Thrombocytopenic Purpura Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 131. Novartis AG Product
Table 132. Novartis AG Recent Development
Table 133. Pfizer Inc. Corporation Information
Table 134. Pfizer Inc. Description and Major Businesses
Table 135. Pfizer Inc. Immune Thrombocytopenic Purpura Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 136. Pfizer Inc. Product
Table 137. Pfizer Inc. Recent Development
Table 138. Global Immune Thrombocytopenic Purpura Therapeutics Sales Forecast by Regions (2021-2026) (K Pcs)
Table 139. Global Immune Thrombocytopenic Purpura Therapeutics Sales Market Share Forecast by Regions (2021-2026)
Table 140. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 141. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share Forecast by Regions (2021-2026)
Table 142. North America: Immune Thrombocytopenic Purpura Therapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 143. North America: Immune Thrombocytopenic Purpura Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 144. Europe: Immune Thrombocytopenic Purpura Therapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 145. Europe: Immune Thrombocytopenic Purpura Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 146. Asia Pacific: Immune Thrombocytopenic Purpura Therapeutics Sales Forecast by Region (2021-2026) (K Pcs)
Table 147. Asia Pacific: Immune Thrombocytopenic Purpura Therapeutics Revenue Forecast by Region (2021-2026) (US$ Million)
Table 148. Latin America: Immune Thrombocytopenic Purpura Therapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 149. Latin America: Immune Thrombocytopenic Purpura Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 150. Middle East and Africa: Immune Thrombocytopenic Purpura Therapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 151. Middle East and Africa: Immune Thrombocytopenic Purpura Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 152. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 153. Key Challenges
Table 154. Market Risks
Table 155. Main Points Interviewed from Key Immune Thrombocytopenic Purpura Therapeutics Players
Table 156. Immune Thrombocytopenic Purpura Therapeutics Customers List
Table 157. Immune Thrombocytopenic Purpura Therapeutics Distributors List
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
List of Figures
Figure 1. Immune Thrombocytopenic Purpura Therapeutics Product Picture
Figure 2. Global Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Type in 2020 & 2026
Figure 3. Eltrombopag Olamine Product Picture
Figure 4. Fostamatinib Disodium Product Picture
Figure 5. GL-2045 Product Picture
Figure 6. Avatrombopag Product Picture
Figure 7. BI-655064 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Application in 2020 & 2026
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Immune Thrombocytopenic Purpura Therapeutics Report Years Considered
Figure 14. Global Immune Thrombocytopenic Purpura Therapeutics Market Size 2015-2026 (US$ Million)
Figure 15. Global Immune Thrombocytopenic Purpura Therapeutics Sales 2015-2026 (K Pcs)
Figure 16. Global Immune Thrombocytopenic Purpura Therapeutics Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Region (2015-2020)
Figure 18. Global Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Region in 2019
Figure 19. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Region (2015-2020)
Figure 20. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Region in 2019
Figure 21. Global Immune Thrombocytopenic Purpura Therapeutics Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Immune Thrombocytopenic Purpura Therapeutics Revenue in 2019
Figure 23. Immune Thrombocytopenic Purpura Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Type (2015-2020)
Figure 25. Global Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Type in 2019
Figure 26. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Type (2015-2020)
Figure 27. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Type in 2019
Figure 28. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Price Range (2015-2020)
Figure 29. Global Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Application (2015-2020)
Figure 30. Global Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Application in 2019
Figure 31. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Application (2015-2020)
Figure 32. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Application in 2019
Figure 33. North America Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 34. North America Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Country in 2019
Figure 36. North America Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Country in 2019
Figure 37. U.S. Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. U.S. Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 40. Canada Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America Immune Thrombocytopenic Purpura Therapeutics Market Share by Type in 2019
Figure 42. North America Immune Thrombocytopenic Purpura Therapeutics Market Share by Application in 2019
Figure 43. Europe Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 44. Europe Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Country in 2019
Figure 46. Europe Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Country in 2019
Figure 47. Germany Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. Germany Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. France Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. U.K. Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Italy Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. Russia Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe Immune Thrombocytopenic Purpura Therapeutics Market Share by Type in 2019
Figure 58. Europe Immune Thrombocytopenic Purpura Therapeutics Market Share by Application in 2019
Figure 59. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 60. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Region in 2019
Figure 62. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Region in 2019
Figure 63. China Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. China Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. Japan Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. South Korea Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. India Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Australia Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Taiwan Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Indonesia Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Thailand Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Malaysia Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Philippines Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Vietnam Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Market Share by Type in 2019
Figure 86. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Market Share by Application in 2019
Figure 87. Latin America Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 88. Latin America Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Country in 2019
Figure 90. Latin America Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Country in 2019
Figure 91. Mexico Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Mexico Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Brazil Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Argentina Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Share by Type in 2019
Figure 98. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Share by Application in 2019
Figure 99. Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 100. Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Country in 2019
Figure 103. Turkey Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Turkey Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. Saudi Arabia Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 108. U.A.E Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Market Share by Type in 2019
Figure 110. Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Market Share by Application in 2019
Figure 111. North America Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. North America Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Europe Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Latin America Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 120. Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed
特発性血小板減少性紫斑病（ITP）治療薬の世界市場（～2026年） ITP (idiopathic thrombocytopenic purpura) is a rare disease with low affliction rates. This disease leads to excessive bruising or bleeding due to the lack of blood platelets. It is also known as immune thrombocytopenia and can affect children and adults alike. Increasing demand for combination ther…- 血栓性血小板減少性紫斑病治療の世界市場（～2026年） Market Analysis and Insights: Global Thrombotic Thrombocytopenic Purpura Treatment Market The global Thrombotic Thrombocytopenic Purpura Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Thrombotic Thrombocytop…
- 紫斑治療の世界市場（～2026年） Purpura is a condition of red or purple discolored spots on the skin that do not blanch on applying pressure. The globally market for purpura treatment is one of the steady growing markets. Purpura occurs when the blood vessels and blood pools under the human skin, result in purple spots on the skin…
- 筋肉内免疫グロブリンの世界市場（～2026年） Market Analysis and Insights: Global Intramuscular Immune Globulin Market The global Intramuscular Immune Globulin market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Intramuscular Immune Globulin Scope and Market Size Int…
- 免疫レパートリーシーケンスの世界市場（～2026年） Immune Repertoire is the collection of B and T cells with functional diversity in the body that reflects the immune selectivity. Immune Repertoire Sequencing means to sequence the complimentary determining region of both B-cell receptor and T-cell receptor. Immune receptor repertoire profiling portr…